Ahmed M, Kakunuri T, Peris L, Meffre D, Yilmaz E, Grewing L
Brain Commun. 2025; 7(1):fcae473.
PMID: 39926615
PMC: 11803424.
DOI: 10.1093/braincomms/fcae473.
Shin H, Kim W, Lee J, Lee H, Nam Y, Kim J
Neuroimage Clin. 2025; 45:103748.
PMID: 39904206
PMC: 11847087.
DOI: 10.1016/j.nicl.2025.103748.
Chen J, Wever D, McNamara N, Bourik M, Smolders J, Hamann J
Front Immunol. 2025; 15:1522381.
PMID: 39877374
PMC: 11772157.
DOI: 10.3389/fimmu.2024.1522381.
Zhu Z, Meng M, Mo S, Wang X, Qiao L
Mol Biotechnol. 2025; .
PMID: 39841378
DOI: 10.1007/s12033-025-01364-1.
Lee C, Jang S, Lim J, Park H, Ahn S, Park S
Exp Mol Med. 2025; 57(1):235-248.
PMID: 39833561
PMC: 11799301.
DOI: 10.1038/s12276-024-01388-8.
Significant oligodendrocyte progenitor and microglial cell death is a feature of remyelination following toxin-induced experimental demyelination.
Gaitsch H, Assinck P, Dimas P, Zhao C, Morcom L, Rowitch D
Brain Commun. 2025; 7(1):fcae386.
PMID: 39830424
PMC: 11739797.
DOI: 10.1093/braincomms/fcae386.
A Lupin () Protein Hydrolysate Decreases the Severity of Experimental Autoimmune Encephalomyelitis: A Preliminary Study.
Cruz-Chamorro I, Alvarez-Lopez A, Santos-Sanchez G, Alvarez-Sanchez N, Pedroche J, Millan-Linares M
Int J Mol Sci. 2025; 26(1.
PMID: 39795896
PMC: 11720533.
DOI: 10.3390/ijms26010032.
Neuronal STING activation mediates inflammation-induced neurodegeneration via ferroptosis pathways in multiple sclerosis.
Wang W, Guo M, Tu X, Jiang M, Zhang C
Biophys Rep. 2025; 10(6):416-417.
PMID: 39758424
PMC: 11693497.
DOI: 10.52601/bpr.2024.240908.
Pathophysiology-Directed Engineering of a Combination Nanoanalgesic for Neuropathic Pain.
Wang W, Wang Y, Huang X, Wu P, Li L, Zhang Y
Adv Sci (Weinh). 2024; 12(8):e2405483.
PMID: 39716944
PMC: 11848598.
DOI: 10.1002/advs.202405483.
Inflammasomes in neurodegenerative diseases.
Wang Q, Yang S, Zhang X, Zhang S, Chen L, Wang W
Transl Neurodegener. 2024; 13(1):65.
PMID: 39710713
PMC: 11665095.
DOI: 10.1186/s40035-024-00459-0.
Overview of emerging therapies for demyelinating diseases.
Medina R, Derias A, Lakdawala M, Speakman S, Lucke-Wold B
World J Clin Cases. 2024; 12(30):6361-6373.
PMID: 39464332
PMC: 11438674.
DOI: 10.12998/wjcc.v12.i30.6361.
The Hidden Hand in White Matter: Pericytes and the Puzzle of Demyelination.
Raj S, Sarangi P, Goyal D, Kumar H
ACS Pharmacol Transl Sci. 2024; 7(10):2912-2923.
PMID: 39421660
PMC: 11480894.
DOI: 10.1021/acsptsci.4c00192.
The Therapeutic Potential of Exosomes from Mesenchymal Stem Cells in Multiple Sclerosis.
Krakenes T, Sandvik C, Ytterdal M, Gavasso S, Evjenth E, Bo L
Int J Mol Sci. 2024; 25(19).
PMID: 39408622
PMC: 11477223.
DOI: 10.3390/ijms251910292.
SIRT6 modulates lesion microenvironment in LPC induced demyelination by targeting astrocytic CHI3L1.
Du J, Yin Y, Wu D, Diao C, Zhao T, Peng F
J Neuroinflammation. 2024; 21(1):243.
PMID: 39342313
PMC: 11438192.
DOI: 10.1186/s12974-024-03241-1.
Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review.
Krsek A, Jagodic A, Baticic L
Medicina (Kaunas). 2024; 60(9).
PMID: 39336425
PMC: 11433843.
DOI: 10.3390/medicina60091384.
BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis.
Bergner C, van der Meer F, Franz J, Vakrakou A, Wurfel T, Nessler S
Brain. 2024; 148(3):908-920.
PMID: 39319704
PMC: 11884765.
DOI: 10.1093/brain/awae293.
Glial Cells as Key Regulators in Neuroinflammatory Mechanisms Associated with Multiple Sclerosis.
Theophanous S, Sargiannidou I, Kleopa K
Int J Mol Sci. 2024; 25(17).
PMID: 39273535
PMC: 11395575.
DOI: 10.3390/ijms25179588.
Assessing disease progression and treatment response in progressive multiple sclerosis.
Comi G, Dalla Costa G, Stankoff B, Hartung H, Soelberg Sorensen P, Vermersch P
Nat Rev Neurol. 2024; 20(10):573-586.
PMID: 39251843
DOI: 10.1038/s41582-024-01006-1.
Transcription Factors Sox8 and Sox10 Contribute with Different Importance to the Maintenance of Mature Oligodendrocytes.
Jorg L, Schlotzer-Schrehardt U, Lefebvre V, Sock E, Wegner M
Int J Mol Sci. 2024; 25(16).
PMID: 39201442
PMC: 11354551.
DOI: 10.3390/ijms25168754.
Remyelinating Drugs at a Crossroad: How to Improve Clinical Efficacy and Drug Screenings.
Al Jaf A, Peria S, Fabiano T, Ragnini-Wilson A
Cells. 2024; 13(16.
PMID: 39195216
PMC: 11352944.
DOI: 10.3390/cells13161326.